Clinical Trial Finder

Inclusion Criteria:

1. Histologically diagnosed as high-grade glioma, failed standard radiotherapy and chemotherapy after surgical resection, with radiological confirmation of recurrence. 2. Aged ≥18 and ≤70 years, regardless of gender. 3. If dexamethasone is administered due to mass effect, the stable daily dose of dexamethasone within 7 days prior to enrollment must be <6 mg, or if the dexamethasone dose is being reduced, the average daily dose within 7 days prior to enrollment must be <6 mg. Patients who receive dexamethasone for reasons other than mass effect may still be eligible for enrollment. 4. Karnofsky performance score ≥40 or WHO performance status score ≤3. 5. Meets the indications for acupuncture therapy, with no severe complications, capable of accepting acupuncture treatment, and demonstrating good compliance. 6. Clear consciousness, able to perceive and distinguish pain, and able to communicate at a basic level. 7. Signed informed consent form and voluntarily agreed to participate in this study.

Exclusion Criteria:

• - 1.

Uncontrolled seizures. 2. Peripheral neuropathy > Grade 1. 3. Currently participating in another clinical trial or have participated in another clinical trial within the past 3 months. 4. Prior treatment with paclitaxel-like chemical or biological compounds, or a history of allergic reactions. 5. Severe dysfunction of the heart, liver, kidneys, or hematologic system (within 14 days prior to treatment: a. Hemoglobin ≥ 90.0 g/L; b. White blood cell count ≥ 3.0 × 10^9/L; c. Absolute neutrophil count ≥ 1500/µL (white blood cell count × neutrophil percentage); d. Platelet count ≥ 100 × 10^9/µL; e. Total bilirubin (TbIL) ≤ 5.0 × ULN; f. Serum AST (SGOT) ≤ 3 × ULN and TbIL ≤ 3.0 × ULN; g. Serum creatinine ≤ 1.5 mg/dL, estimated creatinine clearance ≥ 30 mL/min to < 90 mL/min). 6. Pregnant or breastfeeding women. 7. Diseases affecting cognitive function, such as congenital dementia, or individuals with a history of alcohol, drug, or psychotropic substance abuse.

Arms

Experimental: Treatment group

Patients in the treatment group received both paclitaxel(PTX) and a specific mode electroacupuncture stimulation（SMES） . Drug: Paclitaxel is administered intravenously at a dose of 135-175mg/m², repeated every 3 weeks. Device: SMES immediately after the ABX intravenous infusion began, the patient was placed in a supine position, the skin was routinely disinfected with 75% ethanol, and a stainless steel needle was inserted into GV20 and GV26.Then, the needles are stimulated by using an acupuncture point nerve stimulator with a frequency of 2/100 Hz and an intensity of 3 mA for 40 min (a homemade relay cycled power to the electrode for 6 sec on and 6 sec off).

Interventions

Other: - SMES+PTX

This intervention involves the combined use of medication and device, where the specific mode electroacupuncture stimulation (SMES) intervention is administered simultaneously with the intravenous infusion of paclitaxel.

Drug: - Paclitaxel

Paclitaxel is administered intravenously at a dose of 135-175mg/m², repeated every 3 weeks.

Device: - Specific mode electroacupuncture stimulation

Patients assume a supine position. After routine skin disinfection with 75% ethanol, a stainless steel needle (size 0.25mm×40mm) is inserted into GV20 (Baihui), and another stainless steel needle (size 0.25mm×25mm, as described above) is inserted into GV26 (Shuigou). The acupoints are manually stimulated until the patient experiences soreness, distension, or heaviness (the "De Qi" response). Subsequently, the needles are stimulated using an acupuncture point nerve stimulator (HANS-200, Nanjing Jinsheng Ltd., China) at a frequency of 2/100 Hz and an intensity of 3 mA for 40 minutes (a homemade relay cycled power supply to the electrode, with 6 seconds on and 6 seconds off). The intervention is administered every three weeks, concurrently with paclitaxel treatment